Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Plus Trastuzumab and Pertuzumab in Metastatic HER2+ Breast Cancer
NCT02139358Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Sep 2014
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in breast cancer, sponsored by Moffitt Cancer Center. Primary endpoints: Recommended Phase II Dose at 6 months and Objective Response Rate up to 36 Months. Started Sep 2014; status: completed.
02
Drugs
gemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02139358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02139358.